Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00283790
Status:
COMPLETED
Last Update Posted:
2008-04-03
First Post:
2006-01-27
Brief Title:
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Investigation of Psycliomotor and Cognitive Residual Effects After Single Oral Doses of Zolpidem Tartrate Extended Release 125 mg and Eszopielone 3 mg Compared to Placebo in Healthy Young Volunteers Using Plurazepam 30 mg As An External Comparator
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 125 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers Using Flurazepam 30 mg as an External Comparator
Detailed Description:
This is a crossover study with 4 different treatments Ambien Lunesta placebo and flurazepam The flurazepam arm always comes last due to the long washout period associated with it The other 3 arms are randomized
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None